Sciclone Pharmaceuticals Inc
SCLN
SCLN was delisted on the 13th of October, 2017.
136 hedge funds and large institutions have $366M invested in Sciclone Pharmaceuticals Inc in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 62 increasing their positions, 42 reducing their positions, and 20 closing their positions.
2,400% more call options, than puts
Call options by funds: $25K | Put options by funds: $1K
48% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 42
7% less capital invested
Capital invested by funds: $396M → $366M (-$29.6M)
11% less funds holding
Funds holding: 153 → 136 (-17)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
55% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$75.6M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.14M |
| 3 |
Renaissance Technologies
New York
|
+$3.14M |
| 4 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
+$2.76M |
| 5 |
GP
GLG Partners
London,
United Kingdom
|
+$2.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$5.54M |
| 2 |
SI
Sensato Investors
San Francisco,
California
|
-$3.67M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$2.77M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
-$2.22M |
| 5 |
CAM
ClariVest Asset Management
San Diego,
California
|
-$1.57M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
151
Tower Research Capital (TRC)
New York
| – | -$11K | -974 | Closed |
|
|
EF
152
Empirical Finance
Havertown,
Pennsylvania
| – | -$4K | -315 | Closed |
|
153
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$3K | -287 | Closed |
|
SCLN Hedge Fund Activity: Q1 2017 in Review
136 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q1 2017, worth a combined $366M — down 7.5% from $396M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of SCLN and 9 opened new positions — a net loss of 11 holders — while 42 trimmed existing stakes and 62 added.
The largest buyer was BlackRock, adding an estimated $75.6M. The largest seller was Numeric Investors, cutting an estimated $5.54M.
- 136 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q1 2017, down from 153 in Q4 2016.
- Funds reported $366M of Sciclone Pharmaceuticals Inc stock for Q1 2017, down 7.5% quarter-over-quarter.
- 9 funds opened new Sciclone Pharmaceuticals Inc positions in Q1 2017 and 20 closed out, a net change of -11 holders.
- The largest Sciclone Pharmaceuticals Inc buyer in Q1 2017 was BlackRock, an estimated $75.6M added.
- The largest Sciclone Pharmaceuticals Inc seller in Q1 2017 was Numeric Investors, an estimated $5.54M sold.
Based on aggregated 13F filings for Q1 2017.